Parenteral Delivery of Peptides and Proteins - Challenges in Delivery of Therapeutic Genomics and Proteomics - page 594

[79] Pardridge WM. Peptide drug delivery to the brain. In: Pardridge WM, editor. The blood-
brain barrier and drug delivery to the CNS. New York, NY: Raven Press; 1991. p. 1-357.
[80] Wolf M, Wirth M, Pittner F, Gabor F. Stabilisation and determination of the biological
activity of L-asparaginase in poly(D,L-lactide- co -glycolide) nanospheres. Int J Pharm
2003;256:141-52.
[81] Niu CH, Chiu YY. FDA perspective on peptide formulation and stability issues. J Pharm
Sci 1998;87:1331-4.
[82] Ryff JC, Schellenks H. Immunogenicity of rDNA-derived pharmaceuticals. Trends
Pharmacol Sci 2002;23:254-6.
[83] Davis GC. Protein stability: impact upon protein pharmaceuticals. Biologicals
1993;21:105.
[84] Cleland JL, Daugherty A, Mrsny R. Emerging protein delivery methods. Curr Opin
Biotechnol 2001;12:212-9.
[85] Uchida T, Shiosaki K, Nakada Y, Fukada K, Eda Y, Tokiyoshi S, et al. Microencapsulation
of hepatitis B core antigen for vaccine preparation. Pharm Res 1998;15:1708-13.
[86] Lu W, Park TG. Protein release from poly(lactic- co -glycolic acid) microspheres: protein
stability problems. PDA J Pharm Sci Technol 1995;49:13-19.
[87] Raghuvanshi RS, Goyal S, Singh O, Panda AK. Stabilization of dichloromethane-induced
protein denaturation during microencapsulation. Pharm Dev Technol 1998;3:269-76.
[88] Park TG, Lu W, Crotts G. Importance of in vitro experimental conditions on protein
release kinetics, stability and polymer degradation in protein encapsulated poly(D,L-lactic
acid- co -glycolic acid) microspheres. J Control Release 1995;33:211-22.
[89] Crotts G, Park TG. Protein delivery from poly(lactic- co -glycolic acid) biodegradable
microspheres: release kinetics and stability issues. J Microencapsulation 1998;15:699-713.
[90] Wang W. Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int
J Pharm 1999;185:129-88.
[91] Bilati U, Allemann E, Doelker E. Strategic approaches for overcoming peptide and pro-
tein instability within biodegradable nano- and microparticles. Eur J Pharm Biopharm
2005;59:375-88.
[92] Van der Walle CF, Sharma G, Ravi Kumar M. Current approaches to stabilising and analysing
proteins during microencapsulation in PLGA. Expert Opin Drug Delivery 2009;6:177-86.
[93] van de Weert M, Hennink WE, Jiskoot W. Protein instability in poly(lactic- co -glycolic
acid) microparticles. Pharm Res 2000;17:1159-67.
[94] Schwendeman SP. Recent advances in the stabilization of proteins encapsulated in inject-
able PLGA delivery systems. Crit Rev Ther Drug Carrier Syst 2002;19:73-98.
[95] De Rosa G, Larobina D, La Rotonda MI, Musto P, Quaglia F, Ungaro F. How cyclodex-
trin incorporation affects the properties of protein-loaded PLGA-based microspheres: the
case of insulin/hydroxypropyl--cyclodextrin system. J Control Release 2005;102:71-83.
[96] Li X, Zhang Y, Yan R, Jia W, Yuan M, Deng X, et al. Influence of process parameters on
the protein stability encapsulated in poly-DL-lactide-poly(ethylene glycol) microspheres.
J Control Release 2000;68:41-52.
[97] Jiang W, Schwendeman SP. Stabilization and controlled release of bovine serum albumin
encapsulated in poly(D,L-lactide) and poly(ethylene glycol) microsphere blends. Pharm
Res 2001;18:878-85.
[98] Meinel L, Illi OE, Zapf J, Malfanti M, Peter MH, Gander B. Stabilizing insulin-like growth
factor-I in poly(D,L-lactide-coglycolide) microspheres. J Control Release 2001;70:193-202.
[99] Johansen P, Men Y, Audran R, Corradin G, Merkle HP, Gander B. Improving stability and
release kinetics of microencapsulated tetanus toxoid by co-encapsulation of additives.
Pharm Res 1998;15:1103-9.